Budoprutug

DRUG8 trials

Sponsors

Climb Bio Inc., Tenet Medicines, Climb Bio, Inc.

Conditions

Anti-CD19B CellsBiologicsHealthy VolunteersITPImmune Thrombocytopenia (ITP)MonoclonalPrimary Membranous Nephropathy

Early Phase 1

A Phase 1 Study of Budoprutug (TNT119) Subcutaneous and Intravenous Injections in Normal Healthy Volunteers

CompletedNCT07090655

Climb Bio, Inc.Healthy Volunteers

Start: 2025-08-11End: 2026-04-07Updated: 2026-07-30

Phase 1

Phase 1b/2a in SLE With Budoputug

WithdrawnNCT06570434

Tenet MedicinesB Cells, SLE, Systemic Lupus Erythematosus

Start: 2025-01-31End: 2027-04-30Updated: 2024-10-16

A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE)

RecruitingNCT07011043

Climb Bio, Inc.Systemic Lupus Erythematosus

Start: 2025-07-10End: 2027-04-01Target: 30Updated: 2026-03-27

A Phase 1b/2a, Open-Label, Sequential-Cohort, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Effectiveness of Budoprutug (TNT119) in Subjects with Immune Thrombocytopenia (ITP)

WithdrawnCTIS2024-519745-30-00

Climb Bio Inc.Immune Thrombocytopenia (ITP)

Target: 13Updated: 2025-06-27

A Phase 1b/2a Study of Budoprutug in Subjects With Immune Thrombocytopenia (ITP)

RecruitingNCT07043946

Climb Bio, Inc.Anti-CD19, Biologics, Immune Thrombocytopenia (ITP) +2

Start: 2025-06-30End: 2028-08-01Target: 24Updated: 2026-03-27

A Phase 1b/2a, Open-Label, Sequential-Cohort, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Effectiveness of Budoprutug (TNT119) in Subjects with Immune Thrombocytopenia (ITP)

RecruitingCTIS2024-519745-30-01

Climb Bio Inc.Immune Thrombocytopenia (ITP)

Start: 2025-12-19Target: 13Updated: 2026-01-22

A Phase 1b/2a Study of Budoprutug in Systemic Lupus Erythematosus (SLE)

RecruitingNCT07564596

Climb Bio, Inc.Systemic Lupus Erthematosus

Start: 2026-06-30End: 2027-09-01Target: 30Updated: 2026-08-06

Phase 2

A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy

RecruitingNCT07096843

Climb Bio, Inc.Primary Membranous Nephropathy

Start: 2025-08-25End: 2027-10-01Target: 45Updated: 2026-07-16

Related Papers

A Phase 1b/ 2a study of budoprutug in patients with immune thrombocytopenia (ITP)

Blood2025-11-03